259 related articles for article (PubMed ID: 25404690)
21. Effect of sodium/iodide symporter (NIS)-mediated radioiodine therapy on estrogen receptor-negative breast cancer.
Yao C; Pan Y; Li Y; Xu X; Lin Y; Wang W; Wang S
Oncol Rep; 2015 Jul; 34(1):59-66. PubMed ID: 25955347
[TBL] [Abstract][Full Text] [Related]
22. Modulation of thyroidal radioiodide uptake by oncological pipeline inhibitors and Apigenin.
Lakshmanan A; Scarberry D; Green JA; Zhang X; Selmi-Ruby S; Jhiang SM
Oncotarget; 2015 Oct; 6(31):31792-804. PubMed ID: 26397139
[TBL] [Abstract][Full Text] [Related]
23. In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas.
Cho JY; Shen DH; Yang W; Williams B; Buckwalter TL; La Perle KM; Hinkle G; Pozderac R; Kloos R; Nagaraja HN; Barth RF; Jhiang SM
Gene Ther; 2002 Sep; 9(17):1139-45. PubMed ID: 12170377
[TBL] [Abstract][Full Text] [Related]
24. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.
Kakinuma H; Bergert ER; Spitzweg C; Cheville JC; Lieber MM; Morris JC
Cancer Res; 2003 Nov; 63(22):7840-4. PubMed ID: 14633711
[TBL] [Abstract][Full Text] [Related]
25. Glycosylation of Sodium/Iodide Symporter (NIS) Regulates Its Membrane Translocation and Radioiodine Uptake.
Chung T; Youn H; Yeom CJ; Kang KW; Chung JK
PLoS One; 2015; 10(11):e0142984. PubMed ID: 26599396
[TBL] [Abstract][Full Text] [Related]
26. Mitogen-activated protein kinase signaling enhances sodium iodide symporter function and efficacy of radioiodide therapy in nonthyroidal cancer cells.
Jung KH; Paik JY; Ko BH; Lee KH
J Nucl Med; 2008 Dec; 49(12):1966-72. PubMed ID: 18997042
[TBL] [Abstract][Full Text] [Related]
27. Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas.
Park HJ; Kim JY; Park KY; Gong G; Hong SJ; Ahn IM
Thyroid; 2000 Mar; 10(3):211-7. PubMed ID: 10779135
[TBL] [Abstract][Full Text] [Related]
28. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression.
Cengic N; Baker CH; Schütz M; Göke B; Morris JC; Spitzweg C
J Clin Endocrinol Metab; 2005 Aug; 90(8):4457-64. PubMed ID: 15941870
[TBL] [Abstract][Full Text] [Related]
29. The rs2910164 Genetic Variant of miR-146a-3p Is Associated with Increased Overall Mortality in Patients with Follicular Variant Papillary Thyroid Carcinoma.
Kotlarek M; Kubiak A; Czetwertyńska M; Świerniak M; Gierlikowski W; Kolanowska M; Bakuła-Zalewska E; Jhiang SM; Jażdżewski K; Wójcicka A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495389
[TBL] [Abstract][Full Text] [Related]
30. FoxP3 in papillary thyroid carcinoma induces NIS repression through activation of the TGF-β1/Smad signaling pathway.
Ma S; Wang Q; Ma X; Wu L; Guo F; Ji H; Liu F; Zhao Y; Qin G
Tumour Biol; 2016 Jan; 37(1):989-98. PubMed ID: 26264613
[TBL] [Abstract][Full Text] [Related]
31. A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3',5'-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells.
Taki K; Kogai T; Kanamoto Y; Hershman JM; Brent GA
Mol Endocrinol; 2002 Oct; 16(10):2266-82. PubMed ID: 12351692
[TBL] [Abstract][Full Text] [Related]
32. Hormonal regulation of radioiodide uptake activity and Na+/I- symporter expression in mammary glands.
Cho JY; Léveillé R; Kao R; Rousset B; Parlow AF; Burak WE; Mazzaferri EL; Jhiang SM
J Clin Endocrinol Metab; 2000 Aug; 85(8):2936-43. PubMed ID: 10946907
[TBL] [Abstract][Full Text] [Related]
33. Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein.
Tonacchera M; Viacava P; Agretti P; de Marco G; Perri A; di Cosmo C; de Servi M; Miccoli P; Lippi F; Naccarato AG; Pinchera A; Chiovato L; Vitti P
J Clin Endocrinol Metab; 2002 Jan; 87(1):352-7. PubMed ID: 11788674
[TBL] [Abstract][Full Text] [Related]
34. The miR-146b-3p/PAX8/NIS Regulatory Circuit Modulates the Differentiation Phenotype and Function of Thyroid Cells during Carcinogenesis.
Riesco-Eizaguirre G; Wert-Lamas L; Perales-Patón J; Sastre-Perona A; Fernández LP; Santisteban P
Cancer Res; 2015 Oct; 75(19):4119-30. PubMed ID: 26282166
[TBL] [Abstract][Full Text] [Related]
35. Sodium iodide symporter: its role in nuclear medicine.
Chung JK
J Nucl Med; 2002 Sep; 43(9):1188-200. PubMed ID: 12215558
[TBL] [Abstract][Full Text] [Related]
36. A transporter gene (sodium iodide symporter) for dual purposes in gene therapy: imaging and therapy.
Cho JY
Curr Gene Ther; 2002 Dec; 2(4):393-402. PubMed ID: 12477251
[TBL] [Abstract][Full Text] [Related]
37. miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway.
Shen CT; Qiu ZL; Song HJ; Wei WJ; Luo QY
J Exp Clin Cancer Res; 2016 Jun; 35(1):101. PubMed ID: 27342319
[TBL] [Abstract][Full Text] [Related]
38. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression.
Spitzweg C; Baker CH; Bergert ER; O'Connor MK; Morris JC
Hum Gene Ther; 2007 Oct; 18(10):916-24. PubMed ID: 17931047
[TBL] [Abstract][Full Text] [Related]
39. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
Mitrofanova E; Unfer R; Vahanian N; Link C
Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480
[TBL] [Abstract][Full Text] [Related]
40. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status.
Venkataraman GM; Yatin M; Marcinek R; Ain KB
J Clin Endocrinol Metab; 1999 Jul; 84(7):2449-57. PubMed ID: 10404820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
